{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:52:42Z","timestamp":1775227962461,"version":"3.50.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Iron deficiency is a common comorbidity in heart failure (HF) patients, with up to 50% of ambulatory patients with HF affected. Intravenous (IV) iron therapy has emerged as a promising treatment approach for HF patients with concomitant iron deficiency. This review summarizes the current literature on the use of IV iron therapy in HF patients, focusing on its benefits in improving quality of life, and exercise capacity, and reducing HF hospitalizations. However, concerns about the long-term cardiotoxic effects of IV iron, including the risk of iron overload, are also addressed. The review highlights the importance of a balanced approach to iron replacement and provides an overview of the 2022 American College of Cardiology\/American Heart Association guidelines, which recommend IV iron therapy for eligible patients. Additionally, the review underscores the need for further research, particularly in HF patients with preserved ejection fraction and acute HF. While IV iron therapy shows promise, questions about its safety and specific formulations remain to be fully addressed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000698","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:07:11Z","timestamp":1714122431000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Iron Therapy in Heart Failure Patients With Iron Deficiency: Benefits, Safety, and Guidelines"],"prefix":"10.1097","volume":"34","author":[{"given":"Swati","family":"Chand","sequence":"first","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Arsha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangam","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Medicine, Maharjgunj Medical Campus, Maharjgunj, Nepal."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangharsha","family":"Thapa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"R1-20260403","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure.","volume":"7","author":"von","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R2-20260403","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCULATIONAHA.121.054271","article-title":"Intravenous iron therapy in heart failure with reduced ejection fraction: tackling the deficiency.","volume":"144","author":"Sawicki","year":"2021","journal-title":"Circulation"},{"key":"R3-20260403","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R4-20260403","doi-asserted-by":"crossref","first-page":"e17245","DOI":"10.1016\/j.heliyon.2023.e17245","article-title":"Intravenous iron therapy among patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials.","volume":"9","author":"Hamed","year":"2023","journal-title":"Heliyon"},{"key":"R5-20260403","doi-asserted-by":"crossref","first-page":"e230182","DOI":"10.1155\/2015\/230182","article-title":"Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.","volume":"2015","author":"Gammella","year":"2015","journal-title":"Oxid Med Cell Longev"},{"key":"R6-20260403","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"R7-20260403","doi-asserted-by":"crossref","first-page":"1559S","DOI":"10.3945\/ajcn.117.155804","article-title":"Current understanding of iron homeostasis.","volume":"106","author":"Anderson","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"R8-20260403","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.nutr.012809.104804","article-title":"Iron homeostasis and the inflammatory response.","volume":"30","author":"Wessling-Resnick","year":"2010","journal-title":"Annu Rev Nutr"},{"key":"R9-20260403","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s11886-023-01889-4","article-title":"Treatment of iron deficiency in heart failure.","volume":"25","author":"Shamsi","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"R10-20260403","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CRD.0b013e3181e71150","article-title":"Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.","volume":"18","author":"Jelani","year":"2010","journal-title":"Cardiol Rev"},{"key":"R11-20260403","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry.","volume":"106","author":"von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"R12-20260403","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00392-018-1344-x","article-title":"Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life.","volume":"108","author":"Bekfani","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"R13-20260403","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1002\/ehf2.13661","article-title":"Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study.","volume":"8","author":"Sindone","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R14-20260403","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure.","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R15-20260403","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/ehf2.13245","article-title":"Diagnosis and treatment of iron deficiency in heart failure: OFICSel study by the French Heart Failure Working Group.","volume":"8","author":"Pezel","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R16-20260403","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R17-20260403","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/20009666.2020.1854927","article-title":"Prevalence and association of iron deficiency with anemia among patients with heart failure in the USA: NHANES 2017-2018.","volume":"11","author":"Chobufo","year":"2021","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R18-20260403","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1002\/ehf2.13617","article-title":"Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype.","volume":"8","author":"Fitzsimons","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R19-20260403","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis.","volume":"16","author":"Yeo","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R20-20260403","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R21-20260403","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ejhf.2251","article-title":"Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.","volume":"24","author":"Graham","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"R22-20260403","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R23-20260403","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure.","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"R24-20260403","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamacardio.2019.1739","article-title":"Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF studies.","volume":"4","author":"Grote Beverborg","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R25-20260403","doi-asserted-by":"crossref","first-page":"e004519","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients.","volume":"11","author":"Grote Beverborg","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R26-20260403","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ejhf.2036","article-title":"High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality.","volume":"23","author":"Sierpinski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R27-20260403","doi-asserted-by":"crossref","first-page":"e001012","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"R28-20260403","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijcard.2018.03.039","article-title":"Impact of iron deficiency on long-term clinical outcomes of hospitalized patients with heart failure.","volume":"261","author":"Nakano","year":"2018","journal-title":"Int J Cardiol"},{"key":"R29-20260403","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ejhf.139","article-title":"High prevalence of iron deficiency in patients with acute decompensated heart failure.","volume":"16","author":"Cohen-Solal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R30-20260403","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial.","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"R31-20260403","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.1434","article-title":"Intravenous iron therapy in heart failure: a different perspective.","volume":"21","author":"Ghafourian","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R32-20260403","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ejhf.2092","article-title":"Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study.","volume":"23","author":"Karavidas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R33-20260403","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.","volume":"50","author":"Toblli","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R34-20260403","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency.","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"R35-20260403","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"R36-20260403","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"R37-20260403","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ehf2.12503","article-title":"Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.","volume":"6","author":"Martens","year":"2019","journal-title":"ESC Heart Fail"},{"key":"R38-20260403","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/FJC.0000000000001287","article-title":"IV sodium ferric gluconate complex in patients with iron deficiency hospitalized due to acute heart failure-investigator initiated, randomized controlled trial.","volume":"80","author":"Marcusohn","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"R39-20260403","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet (London, England)"},{"key":"R40-20260403","doi-asserted-by":"crossref","first-page":"e008100","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","article-title":"Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design.","volume":"14","author":"Mentz","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R43-20260403","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations.","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"R44-20260403","doi-asserted-by":"crossref","first-page":"e224488","DOI":"10.1001\/jamanetworkopen.2022.4488","article-title":"Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions.","volume":"5","author":"Arastu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R45-20260403","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"key":"R46-20260403","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R47-20260403","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ejhf.1202","article-title":"Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.","volume":"20","author":"Iorio","year":"2018","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:07:27Z","timestamp":1775225247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000698","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}